https://www.selleckchem.com/products/gcn2ib.html
Across diagnostic periods, use of CurTrt increased from 15% to 51% in men aged ≥70 and 65% to 81% in men aged70years. With median five years follow-up, PCSM decreased in all patients (P.05), in the third period restricted to senior adults. In all patients NoCurTrt was associated with three-fold higher 5-year PCSM and two-fold higher OM compared to CurTrt. In high-risk PCa patients, increased use of CurTrt, greatest in senior men, was observed along with decreased PCSM and OM in both senior and younger adults. CurTrt should increa